Guntinas-Lichius O, Kreppel M P, Stuetzer H, Semrau R, Eckel H E, Mueller R P
Clinic of Otorhinolaryngology, Head and Neck Surgery, University of Cologne, D-50924 Koeln, Germany.
Eur J Surg Oncol. 2007 Mar;33(2):222-8. doi: 10.1016/j.ejso.2006.10.033. Epub 2006 Nov 28.
To assess the single and multimodal treatment results and prognostic factors for sinonasal carcinoma.
Overall survival (OS), disease-specific survival (DSS), local control (LC), and disease-free survival (DFS) in 229 patients with sinonasal carcinoma treated from 1967 to 2003 were calculated. Prognostic factors were univariately and multivariately analyzed. The median follow-up period for survivors was 126 months.
32% of the patients were operated only, 47% underwent multimodal therapy, and 20% were treated without operation. The 5-year OS rate was 41%, and the DSS rate was 51%. The LC rate was 64%, and the DFS rate was 34%. Prognostic for DSS were M status (p<0.001), UICC stage (p<0.001), T classification (p=0.001), N status (p=0.002), intracranial tumor infiltration (p=0.008), infiltration of the pterygopalatine fossa (p=0.02), infiltration of the skull base (p=0.021), infiltration of the orbita (p=0.041), and the type of therapy (p<0.001): The 5-year DSS rate was 63% for patients operated only, 56% for all operated patients, 46% for patients undergoing surgery and radiotherapy, but only 21% for patients treated with radiotherapy+/-chemotherapy. Multivariate analysis revealed that T classification (p=0.042), N classification (p=0.035), M classification (p=0.007), UICC stage (p=0.038), and type of therapy (p=0.038) were independent prognostic factors for DSS.
Radical surgery is recommended for stage I/II sinonasal carcinomas. Stage III/IV carcinomas still have a poor prognosis, but multimodal treatment seems to favor the outcome.
评估鼻窦癌的单模式和多模式治疗结果及预后因素。
计算了1967年至2003年期间接受治疗的229例鼻窦癌患者的总生存期(OS)、疾病特异性生存期(DSS)、局部控制率(LC)和无病生存期(DFS)。对预后因素进行单因素和多因素分析。幸存者的中位随访期为126个月。
32%的患者仅接受手术治疗,47%接受多模式治疗,20%未接受手术治疗。5年总生存率为41%,疾病特异性生存率为51%。局部控制率为64%,无病生存率为34%。疾病特异性生存的预后因素为M状态(p<0.001)、国际抗癌联盟(UICC)分期(p<0.001)、T分级(p=0.001)、N状态(p=0.002)、颅内肿瘤浸润(p=0.008)、翼腭窝浸润(p=0.02)、颅底浸润(p=0.021)、眼眶浸润(p=0.041)以及治疗类型(p<0.001):仅接受手术治疗的患者5年疾病特异性生存率为63%,所有接受手术治疗的患者为56%,接受手术和放疗的患者为46%,但接受放疗加/减化疗的患者仅为21%。多因素分析显示,T分级(p=0.042)、N分级(p=0.035)、M分级(p=0.007)、UICC分期(p=0.038)和治疗类型(p=0.038)是疾病特异性生存的独立预后因素。
对于I/II期鼻窦癌,建议行根治性手术。III/IV期癌症的预后仍然较差,但多模式治疗似乎有利于改善预后。